Breaking News Instant updates and real-time market news.

GPN

Global Payments

$172.38

3.17 (1.87%)

, V

Visa

$180.90

1.95 (1.09%)

07:58
11/04/19
11/04
07:58
11/04/19
07:58

Global Payments price target raised to $186 from $162 at BMO Capital

BMO Capital analyst James Fotheringham raised his price target on Global Payments (GPN) to $186 after its Q3 revenue beat driven by better margin and stronger growth in Europe in spite of the Brexit related concerns. The analyst adds that while the company also provided higher synergy targets, he is keeping his Market Perform rating on the stock with preference toward Visa (V), MasterCard (MA), and PayPal (PYPL) due to more attractive valuations.

GPN

Global Payments

$172.38

3.17 (1.87%)

V

Visa

$180.90

1.95 (1.09%)

MA

MasterCard

$279.02

1.96 (0.71%)

PYPL

PayPal

$104.98

0.92 (0.88%)

  • 13

    Nov

  • 21

    Nov

  • 10

    Dec

GPN Global Payments
$172.38

3.17 (1.87%)

10/14/19
10/14/19
INITIATION

Buy
Global Payments initiated with a Buy at UBS
As previously reported, UBS analyst Eric Wasserstrom initiated coverage of Global Payments with a Buy rating and $193 price target. The analyst believes that following the TSYS acquisition, Global Payments should sees 8%-9% revenue growth, and that the combination of revenue growth, mix, and cost synergies should create "significant margin expansion." These factors should drive positive EPS revisions and support revaluation of Global Payments shares.
10/30/19
JPMS
10/30/19
INITIATION
Target $198
JPMS
Overweight
Global Payments reinstated with an Overweight at JPMorgan
JPMorgan analyst Tien-tsin Huang reinstated coverage of Global Payments with an Overweight rating and December 2020 price target of $198 following a period of restriction. The firm had an Overweight rating and December 2019 price target of $151 prior to restriction. The analyst likes the TSS transaction, saying it Global Payments "valuable operational and financial scale, while reducing leverage."
10/30/19
10/30/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Global Payments (GPN) reinstated with an Overweight at JPMorgan. 2. Gossamer Bio (GOSS) initiated with a Buy at Berenberg. 3. Health Catalyst (HCAT) initiated with an Overweight at Cantor Fitzgerald. 4. GW Pharmaceuticals (GWPH) initiated with a Buy at H.C. Wainwright while Sage Therapeutics (SAGE) was initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/19
OPCO
11/01/19
NO CHANGE
Target $192
OPCO
Outperform
Global Payments price target raised to $192 from $178 at Oppenheimer
Oppenheimer analyst Glenn Greene raised his price target for Global Payments to $192 from $178 and reiterated an Outperform rating after the company's "solid" Q3 report, with included double digit organic constant currency revenue growth. Greene says shares remain "quite attractive."
V Visa
$180.90

1.95 (1.09%)

10/25/19
RAJA
10/25/19
NO CHANGE
Target $205
RAJA
Outperform
Visa price target raised to $205 from $193 at Raymond James
Raymond James analyst John Davis raised his price target for Visa to $205 from $193 and reiterated an Outperform rating following a "solid" Q4 print and "encouraging" initial 2020 guidance. Aside from the better top-line outlook, Davis tells investors in a research note that there were few surprises as Visa continues to execute and we expect the company to drive at least mid-teens earnings growth for the foreseeable future. He continues to recommend the stock and believes investors should take advantage of the recent rotation out of growth stocks and add to positions.
10/31/19
BMOC
10/31/19
NO CHANGE
Target $348
BMOC
Outperform
MasterCard price target raised to $348 from $328 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on MasterCard (MA) to $348 and kept his Outperform rating after its "broad-based" Q3 earnings beat. The analyst believes that the company can grow its revenue faster than previously expected given its exposure to fast-growing international markets, B2B payment flows, and cross-border volume, offsetting its indicated higher marketing spend. Fotheringham prefers Visa (V) to MasterCard however due to a relative valuation discount.
10/28/19
BMOC
10/28/19
NO CHANGE
Target $239
BMOC
Outperform
Visa price target raised to $239 from $231 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Visa to $239 and kept his Outperform rating after its Q4 earnings beat and encouraging FY20 guidance driven by improved incentives, reduced operating costs, and lower assumed tax rate. The analyst further cites "encouraging" FY20 guidance, adding that the stock remains his top recommendation among U.S.financial technology, large-cap banks, specialty lenders, and asset manager companies. Fotheringham also raises his FY21 EPS view on Visa by 6c to $7.41.
10/25/19
JEFF
10/25/19
NO CHANGE
Target $210
JEFF
Buy
Visa setup attractive for 2020, says Jefferies
Visa reported a 3% earnings beat relative to consensus driven by top-line upside and a lower tax rate, Jefferies analyst Trevor Williams tells investors in a research note. The analyst views the company's fiscal 2020 guide as better than some feared and believes it implies continued momentum from the second half of 2019 through 2020. He continues to like the near-term setup for the shares and keeps a Buy rating on the name with a $210 price target.
MA MasterCard
$279.02

1.96 (0.71%)

09/13/19
RHCO
09/13/19
NO CHANGE
Target $325
RHCO
Buy
MasterCard price target raised to $325 from $310 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard (MA) to $325 and kept his Buy rating, saying he expects the company to maintain its 10% or more EBITDA premium relative to Visa (V) and PayPal (PYPL). The analyst believes that MasterCard has a more durable organic revenue growth and offers a "differentiated competitive strategy" with its Real-Time Payments, adding that its monetization can be bolstered further by B2B products, cross-border payments, bill payments, point-of-sale technology, and other initiatives.
10/01/19
ADAM
10/01/19
NO CHANGE
Target $118
ADAM
Buy
PayPal payment processor deal beats card networks to China, says Canaccord
Canaccord analyst Joseph Vafi said Paypal's (PYPL) disclosure of its controlling stake in Chinese payment player GoPay has material strategic implications longer term. The analyst notes the deal allowed PayPal to beat both Visa (V) and Mastercard (MA) into the Chinese market and could be a conduit to drive meaningful cross-border payments volume allowing it to continue to sustain mid 20% payment volume for the next several years. Vafi reiterated his Buy rating and $118 price target on PayPal shares.
09/16/19
MSCO
09/16/19
NO CHANGE
Target $315
MSCO
Overweight
MasterCard price target raised to $315 from $291 at Morgan Stanley
Morgan Stanley analyst James Faucette raised his price target on MasterCard shares to $315 from $291 following the company's Investment Community Meeting last week. The intra-quarter data shared by the company should ease some near-term macro concerns and the event left him feeling confident in "the key pillars" of his Overweight thesis, Faucette tells investors. MasterCard is also making notable progress on its longer term initiatives, which should support growth beyond the company's 3-year outlook, added Faucette.
PYPL PayPal
$104.98

0.92 (0.88%)

10/29/19
NOMU
10/29/19
NO CHANGE
Target $49
NOMU
Reduce
Square valuation 'lofty' and 'unsustainable,' says Nomura Instinet
Nomura Instinet analyst Bill Carcache keeps a Reduce rating on Square (SQ) with a $49 price target saying the company's valuation as "lofty" and "unsustainable." While certain elements of valuation are subjective, fundamentals don't support Square's premium, Carcache tells investors in a research note titled "Why SQ's Valuation Just Doesn't Square." He believes the company's growth rate is on the verge of falling below PayPal's (PYPL) despite the fact that PayPal is growing off of a base that is five-to-six times larger. In addition, while bulls will argue that growth will accelerate after Square invests the proceeds from the sale of Caviar, investors should be skeptical of companies "that are chasing growth at the expense of returns," contends Carcache.
10/24/19
MSCO
10/24/19
NO CHANGE
Target $129
MSCO
Overweight
PayPal Q3 a step towards allaying competition, macro fears, says Morgan Stanley
Morgan Stanley analyst James Faucette said PayPal's (PYPL) soft results in the first half of the year "fed fuel to the bear case" that ongoing growth of Apple Pay (AAPL) was starting to impact PayPal's growth, although he doesn't think that Apple Pay's on-line acceptance is high enough to have had much impact. Given a surge in transaction volumes, new accounts and positive moves on pricing, he views the company's Q3 results as "a step towards allaying fears related to competition and macro conditions," Faucette tells investors. He keeps an Overweight rating and $129 price target on PayPal shares.
10/24/19
CHLM
10/24/19
NO CHANGE
Target $120
CHLM
Buy
PayPal price target lowered to $120 from $140 at Craig-Hallum
Craig-Hallum analyst Bradley Berning lowered his price target for PayPal (PYPL) to $120 from $140 saying that while networking effect drives revenue flywheel and margin surprise, eBay (EBAY) is a temporary headwind to 2020/2021 pace of margin expansion. The analyst reiterates a Buy rating on PayPal's shares.
10/24/19
RHCO
10/24/19
NO CHANGE
Target $105
RHCO
Hold
PayPal price target lowered to $105 from $115 at SunTrust
SunTrust analyst Andrew Jeffrey lowered his price target on PayPal to $105 and kept his Hold rating after its Q3 results. The analyst notes that investors should cheer the high-teen revenue growth quarter and strong operating leverage, but he remains concerned about the company's long-term competitive position relative to next-generation "tech stacks" and given the emerging network e-commerce solutions. Jeffrey adds that PayPal's margin gains may be eroded as the company has "already benefited" from its efficiency initiatives.

TODAY'S FREE FLY STORIES

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.